報價延遲最少15分鐘:2026/04/15 11:57 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.535 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.90/-0.74
|
|
企業價值
1.17B
|
| 資產負債 |
|
每股賬面淨值
-0.16
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
4.48M
|
|
每股收益
0.07
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise andexperience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline ofearlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. |
